PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

No treatment effect observed in this patient population; substantial improvement in 6-minute walk test seen in both placebo and active groups
Study adds to growing body of data supporting strong safety and tolerability profile of LYT-100 (deupirfenidone)
Company will drive LYT-100 forward in other indications, with a focus on IPF where human clinical efficacy has been previously shown with pirfenidone
BOSTON, June 14, 2022 –( BUSINESS WIRE )– PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 …

Read the source article at sg.finance.yahoo.com
2022-06-14 06:00:00